| Autor: |
Mary Baker, Damien Bové, Tom Isaacs, Ken Paterson, Angelo Antonini, Reijo Salonen |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Scopus-Elsevier |
| ISSN: |
1758-3837 |
| DOI: |
10.17925/enr.2012.07.s1.36 |
| Popis: |
A major barrier to optimal care in Parkinson’s disease (PD) is the many years it takes for patients to gain access to new therapies and the best neurological services. A new treatment has to overcome many hurdles to become a clinically and cost-effective new therapy for patients, for example, gaining regulatory approval and reimbursement. Sharing opinions between the industry, neurologists, patients and other stakeholders about the benefits and risks of new treatments is important in influencing this process. The complex chain of events that currently characterises the development of new treatments for PD could be enhanced and accelerated by group discussions and collaborative care – right from the outset of the development process. Developing the process in this way would optimise patients’ receipt of the best treatments in a timely manner. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
